BRPI0914406A2 - composto, composição farmacêutica, e, método para aumentar os níveis no plasma de apo a1 em um mamífero - Google Patents

composto, composição farmacêutica, e, método para aumentar os níveis no plasma de apo a1 em um mamífero

Info

Publication number
BRPI0914406A2
BRPI0914406A2 BRPI0914406A BRPI0914406A BRPI0914406A2 BR PI0914406 A2 BRPI0914406 A2 BR PI0914406A2 BR PI0914406 A BRPI0914406 A BR PI0914406A BR PI0914406 A BRPI0914406 A BR PI0914406A BR PI0914406 A2 BRPI0914406 A2 BR PI0914406A2
Authority
BR
Brazil
Prior art keywords
mammal
compound
pharmaceutical composition
plasma levels
increasing apo
Prior art date
Application number
BRPI0914406A
Other languages
English (en)
Portuguese (pt)
Inventor
Barbara Staehelin
Daniel Bellus
Herman Kempen
Original Assignee
Circomed Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Circomed Llc filed Critical Circomed Llc
Publication of BRPI0914406A2 publication Critical patent/BRPI0914406A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D495/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
BRPI0914406A 2008-10-30 2009-10-29 composto, composição farmacêutica, e, método para aumentar os níveis no plasma de apo a1 em um mamífero BRPI0914406A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP08167982 2008-10-30
PCT/EP2009/064243 WO2010049466A1 (en) 2008-10-30 2009-10-29 Thienotriazolodiazepine derivatives active on apo a

Publications (1)

Publication Number Publication Date
BRPI0914406A2 true BRPI0914406A2 (pt) 2015-10-20

Family

ID=40380148

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0914406A BRPI0914406A2 (pt) 2008-10-30 2009-10-29 composto, composição farmacêutica, e, método para aumentar os níveis no plasma de apo a1 em um mamífero

Country Status (11)

Country Link
US (1) US8569288B2 (enExample)
EP (1) EP2362876B1 (enExample)
JP (1) JP5490811B2 (enExample)
KR (1) KR101633742B1 (enExample)
CN (1) CN102292341B (enExample)
AU (1) AU2009309691B2 (enExample)
BR (1) BRPI0914406A2 (enExample)
CA (1) CA2741934C (enExample)
EA (1) EA018620B1 (enExample)
ES (1) ES2448567T3 (enExample)
WO (1) WO2010049466A1 (enExample)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2118074E (pt) 2007-02-01 2014-03-20 Resverlogix Corp Compostos para a prevenção e tratamento de doenças cardiovasculares
KR101803259B1 (ko) 2009-03-18 2017-11-30 리스버로직스 코퍼레이션 신규한 소염제
SI2421533T1 (sl) 2009-04-22 2019-01-31 Resverlogix Corp. Nova protivnetna sredstva
MX362384B (es) 2010-05-14 2019-01-15 Dana Farber Cancer Inst Inc Composiciones y metodos para tratar neoplasias, enfermedades inflamatorias y otros trastornos.
CA2799373A1 (en) * 2010-05-14 2011-11-17 Dana-Farber Cancer Institute, Inc. Compositions and methods for modulating metabolism
CA2799381A1 (en) * 2010-05-14 2011-11-17 Dana-Farber Cancer Institute, Inc. Male contraceptive compositions and methods of use
MX354217B (es) 2010-05-14 2018-02-19 Dana Farber Cancer Inst Inc Composiciones y metodos para el tratamiento de leucemia.
WO2012075456A1 (en) 2010-12-02 2012-06-07 Constellation Pharmaceuticals Bromodomain inhibitors and uses thereof
AR084070A1 (es) 2010-12-02 2013-04-17 Constellation Pharmaceuticals Inc Inhibidores del bromodominio y usos de los mismos
EP2705039B1 (en) 2011-05-04 2017-07-26 Constellation Pharmaceuticals, Inc. Bromodomain inhibitors and uses thereof
WO2012174487A2 (en) 2011-06-17 2012-12-20 Constellation Pharmaceuticals, Inc. Bromodomain inhibitors and uses thereof
EP2864336B1 (en) 2012-06-06 2016-11-23 Constellation Pharmaceuticals, Inc. Benzo[b]isoxazoloazepine bromodomain inhibitors and uses thereof
TWI602820B (zh) 2012-06-06 2017-10-21 星宿藥物公司 溴域抑制劑及其用途
KR20160034379A (ko) 2013-07-25 2016-03-29 다나-파버 캔서 인스티튜트 인크. 전사 인자의 억제제 및 그의 용도
WO2015070020A2 (en) 2013-11-08 2015-05-14 Dana-Farber Cancer Institute, Inc. Combination therapy for cancer using bromodomain and extra-terminal (bet) protein inhibitors
RU2016134947A (ru) 2014-01-31 2018-03-01 Дана-Фарбер Кансер Институт, Инк. Производные диаминопиримидин бензолсульфона и их применение
WO2015117087A1 (en) 2014-01-31 2015-08-06 Dana-Farber Cancer Institute, Inc. Uses of diazepane derivatives
AU2015222805B2 (en) 2014-02-28 2020-05-21 Tensha Therapeutics, Inc. Treatment of conditions associated with hyperinsulinaemia
CA2952830C (en) 2014-06-20 2022-11-01 Constellation Pharmaceuticals, Inc. Crystalline forms of 2-((4s)-6-(4-chlorophenyl)-1-methyl-4h-benzo[c]isoxazolo[4,5-e]azepin-4-yl)acetamide
EP3177626A4 (en) 2014-08-08 2017-12-27 Dana Farber Cancer Institute, Inc. Diazepane derivatives and uses thereof
BR112017002190A2 (pt) 2014-08-08 2017-11-21 Dana Farber Cancer Inst Inc derivados de di-hidropteridinona e usos dos mesmos
US10124009B2 (en) 2014-10-27 2018-11-13 Tensha Therapeutics, Inc. Bromodomain inhibitors
CN114984016A (zh) 2015-03-13 2022-09-02 雷斯韦洛吉克斯公司 用于治疗补体相关疾病之组合物及治疗方法
AU2016276963C1 (en) 2015-06-12 2021-08-05 Dana-Farber Cancer Institute, Inc. Combination therapy of transcription inhibitors and kinase inhibitors
CN108472300A (zh) 2015-09-11 2018-08-31 达纳-法伯癌症研究所股份有限公司 氰基噻吩并三唑并二氮杂环庚三烯及其用途
US10881668B2 (en) 2015-09-11 2021-01-05 Dana-Farber Cancer Institute, Inc. Acetamide thienotriazolodiazepines and uses thereof
MX2018006499A (es) * 2015-11-25 2018-08-01 Dana Farber Cancer Inst Inc Inhibidores de bromodominio bivalentes y usos de los mismos.
MX2020013608A (es) 2018-06-13 2021-03-09 Worg Pharmaceuticals Hangzhou Co Ltd Preparacion de derivados de triazepina condensados y su uso como inhibidores de bet.

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4155913A (en) * 1973-02-08 1979-05-22 Hoffmann-La Roche Inc. Thienotriazolodiazepine derivatives
DE3435973A1 (de) * 1984-10-01 1986-04-10 Boehringer Ingelheim KG, 6507 Ingelheim Diazepine enthaltende pharmazeutische zusammensetzungen mit paf-antagonistischer wirkung
DE3878833T2 (de) * 1987-05-28 1993-06-09 Yoshitomi Pharmaceutical Thieno(triazolo)diazepinverbindungen, und medizinische verwendung derselben.
JPH11512107A (ja) * 1995-09-09 1999-10-19 エフ・ホフマン−ラ ロシュ アーゲー チエノトリアゾロジアゼピンのアポリポタンパク質ａ−ｉレベル増加のための用途
US6444664B1 (en) * 1997-04-18 2002-09-03 Nederlandse Organisatie Voor Toegepast - Natuurweten Schappelijk Onderzoek (Tno) Method for controlling the plasma level of lipoproteins to treat alzheimeris disease

Also Published As

Publication number Publication date
CN102292341B (zh) 2014-09-10
AU2009309691B2 (en) 2015-04-02
WO2010049466A1 (en) 2010-05-06
JP5490811B2 (ja) 2014-05-14
CA2741934C (en) 2016-09-13
EP2362876A1 (en) 2011-09-07
EA018620B1 (ru) 2013-09-30
ES2448567T3 (es) 2014-03-14
JP2012506896A (ja) 2012-03-22
EP2362876B1 (en) 2013-12-11
AU2009309691A1 (en) 2010-05-06
US20110230460A1 (en) 2011-09-22
CA2741934A1 (en) 2010-05-06
CN102292341A (zh) 2011-12-21
US8569288B2 (en) 2013-10-29
EA201100698A1 (ru) 2011-12-30
KR20110091523A (ko) 2011-08-11
KR101633742B1 (ko) 2016-06-27

Similar Documents

Publication Publication Date Title
BRPI0914406A2 (pt) composto, composição farmacêutica, e, método para aumentar os níveis no plasma de apo a1 em um mamífero
BRPI0921317A2 (pt) composto, composição farmacêutica, e, método para tratar ou prevenir uma patologia relacionada com abeta em um mamífero
BRPI0909691A2 (pt) Composto, método para preparar um composto, e, composição farmacêutica
BRPI0923384A2 (pt) composto, composição farmacêutica, e, métodos para tratar um mamífero, e para inibir quimiotaxia celular
BRPI0905717A2 (pt) Composição farmacêutica, processo para preparar uma composição farmacêutica e forma de dosagem farmacêutica
BRPI0818533A2 (pt) composto, composição farmacêutica, e, processo para a preparação de um composto
BRPI0906906A2 (pt) Método para preparar um composto e composto
BRPI0910072A2 (pt) composto, composição farmaceutic, e, método para prover anestesia a um mamífero.
BRPI0906962A2 (pt) Composto, e, composição farmacêutica
BRPI0906556A2 (pt) Composto, e, composição farmacêutica
BRPI0813306A2 (pt) composto, composição farmacêutica, método para produzir a inibição de uma cisteína protease em um mamífero, e, uso de um composto.
BRPI0912384A2 (pt) composição, e, método para preparar uma composição
NO20085322L (no) Fremgangsmate for raskere ansiktsdeteksjon
BRPI0921106A2 (pt) biocombustível e processo para preparação de biocombustível
BRPI0917681A2 (pt) Composto, e, composição farmacêutica
BR112013008008A2 (pt) composto, composição farmacêutica e processo para preparar um composto
BRPI0814821A2 (pt) Composto, composição farmacêutica, e, processo para preparar um composto
BRPI0917952A2 (pt) método para fabricaar um componente de revestimento para um moinho, e, componente de revistimento para um moinho
BRPI0916000A2 (pt) formulação farmacêutica de liberação modificada, e, método para tratar um distúrbio
BRPI1016109A2 (pt) "composto, composição farmacêutica, e, processo para preparar um composto"
BRPI0914182A2 (pt) composto, e, composição farmacêutica
BRPI0811238A2 (pt) Composto, uso de um composto, composição farmacêutica, e, método para tratar um distúrbio
BRPI0909267A2 (pt) composição farmacêutica, processo para a preparação de uma composição farmacêutica, e, métodos para tratar um animal de sangue quente que sofre de um a condição e para tratar o câncer em um animal de sangue quente
BRPI0917375A2 (pt) composicoes e metodos para fornecimento de um beneficio
BRPI0814011A2 (pt) método para preparação de biobutanol

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2485 DE 21-08-2018 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI